Brokerages expect Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) to report earnings per share of ($0.54) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Concert Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.58) and the highest estimate coming in at ($0.49). Concert Pharmaceuticals reported earnings per share of ($0.51) during the same quarter last year, which indicates a negative year-over-year growth rate of 5.9%. The company is expected to issue its next earnings results on Tuesday, November 14th.

According to Zacks, analysts expect that Concert Pharmaceuticals will report full year earnings of $4.24 per share for the current fiscal year, with EPS estimates ranging from ($2.04) to $10.51. For the next financial year, analysts forecast that the business will post earnings of ($2.12) per share, with EPS estimates ranging from ($2.48) to ($1.75). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Concert Pharmaceuticals.

Concert Pharmaceuticals (NASDAQ:CNCE) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.04. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.20 million. Concert Pharmaceuticals had a negative net margin of 60,681.70% and a negative return on equity of 61.98%.

A number of equities research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of Concert Pharmaceuticals in a research note on Friday. Stifel Nicolaus reiterated a “buy” rating and issued a $30.00 price objective on shares of Concert Pharmaceuticals in a research note on Sunday. Zacks Investment Research upgraded Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 10th. Finally, BidaskClub cut Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $24.80.

In other Concert Pharmaceuticals news, insider Ryan Lynch sold 3,500 shares of the company’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $14.51, for a total value of $50,785.00. Following the sale, the insider now owns 9,500 shares of the company’s stock, valued at $137,845. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.10% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the business. American International Group Inc. grew its holdings in Concert Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,156 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 677 shares during the last quarter. Alliancebernstein L.P. acquired a new stake in Concert Pharmaceuticals in the second quarter valued at $174,000. State of Wisconsin Investment Board acquired a new stake in Concert Pharmaceuticals in the second quarter valued at $181,000. The Manufacturers Life Insurance Company grew its holdings in Concert Pharmaceuticals by 1.9% in the second quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock valued at $210,000 after purchasing an additional 287 shares during the last quarter. Finally, Airain ltd acquired a new stake in Concert Pharmaceuticals in the second quarter valued at $215,000. 61.62% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “-$0.54 Earnings Per Share Expected for Concert Pharmaceuticals, Inc. (CNCE) This Quarter” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/23/0-54-earnings-per-share-expected-for-concert-pharmaceuticals-inc-cnce-this-quarter.html.

Shares of Concert Pharmaceuticals (CNCE) opened at 16.09 on Monday. The stock’s market capitalization is $365.03 million. The firm’s 50 day moving average is $14.94 and its 200 day moving average is $14.66. Concert Pharmaceuticals has a 52-week low of $7.11 and a 52-week high of $19.11.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Get a free copy of the Zacks research report on Concert Pharmaceuticals (CNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.